Prognostic Factors for Melanoma

Dermatologic Clinics

Volumn 30, Issue 3, 2012, Pages 469-485

  Wisco, Oliver J ^a,b   Sober, Arthur J ^b  

^a KEESLER MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Biomarkers; Histology; Melanoma; Prognosis; Survival

Indexed keywords

LACTATE DEHYDROGENASE;

ADVANCED CANCER; AGE; CANCER INVASION; CANCER PROGNOSIS; CANCER STAGING; CUTANEOUS MELANOMA; DATA BASE; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS; ETHNIC DIFFERENCE; GENDER; GENE MUTATION; GRAFT RECIPIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG METASTASIS; LYMPH NODE METASTASIS; MARKER GENE; MICROMETASTASIS; MITOSIS RATE; ONCOGENE; ONCOGENE BRAF; ONCOGENE N RAS; ONCOLOGICAL PARAMETERS; ORGAN TRANSPLANTATION; PREDICTION; PREGNANCY; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; SATELLITE METASTASIS; SENTINEL LYMPH NODE BIOPSY; SKIN ULCER; SOCIOECONOMICS; SURVIVAL RATE; TUMOR CLASSIFICATION; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR THICKNESS; TUMOR VOLUME;

HUMANS; MELANOMA; NEOPLASM STAGING; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84863870578     PISSN: 07338635     EISSN: 15580520     Source Type: Journal    
DOI: 10.1016/j.det.2012.04.008     Document Type: Review

References (65)

1. Clark W.H., From L., Bernardino E.A., et al. The histogenesis and biological behavior of primary human malignant melanomas of the skin. Cancer Res 1969, 29:705-726.
2. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970, 172:902-908.
3. Clark W.H., Elder D.E., Guerry D., et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989, 81:1893-1904.
4. Balch C.M., Gershenwald J.E., Soong S.J., et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27:6199-6206.
5. Spatz A., Batist G., Eggermont A.M. The biology behind prognostic factors of cutaneous melanoma. Curr Opin Oncol 2010, 22:163-168.
6. Balch C.M., Gershenwald J.E., Soong S.J., et al. Melanoma of the skin. AJCC staging manual 2010, 325-344. Springer, New York. 7th edition. S.B. Edge, D.R. Byrd, C.C. Compton (Eds.).
7. Balch C.M., Gershenwald J.E., Soong S.J., et al. Update on the melanoma staging system: the importance of sentinel node staging and primary tumor mitotic rate. J Surg Oncol 2011, 104:379-385.
8. Payette M.J., Katz M., Grant-Kels J.M. Melanoma prognostic factors found in the dermatopathology report. J Clin Dermatol 2009, 27:53-74.
9. Sarpa H.G., Reinke K., Shaikh L., et al. Prognostic significance of extent of ulceration in primary cutaneous melanoma. Am J Surg Pathol 2006, 30:1396-1400.
10. Balch C.M., Atkins M.B., Buzaid A.C., et al. Melanoma of the skin. AJCC staging manual 2002, 209-220. Springer, New York. 6th edition. F.L. Green, D.L. Page, I.D. Fleming (Eds.).
11. Morton D.L., Thompson J.F., Cochran A.J., et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006, 355:1307-1317.
12. Gershenwald J.E., Ross M.I. Sentinel-lymph-node biopsy for cutaneous melanoma. N Engl J Med 2011, 364:1738-1745.
13. Balch C.M., Gershenwald J.E., Soong S.J., et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 2010, 28:2452-2459.
14. Ohsie S.J., Sarantopoulos G.P., Ochran A.J., et al. Immunohistochemical characteristics of melanoma. J Cutan Pathol 2008, 35:433-444.
15. Van Akkooi A.C., de Wilt J.H., Verhoef C., et al. Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative?. Ann Oncol 2006, 17:1578-1585.
16. Scheri R.P., Essner R., Turner R.R., et al. Isolated tumor cells in the sentinel node affect long-term prognosis of patients with melanoma. Ann Surg Oncol 2007, 14:2861-2866.
17. van der Pleog A.P., van Akkooi A.C., Rutkowski P., et al. Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. J Clin Oncol 2011, 29:2206-2214.
18. Satzger I., Volker B., Al Ghazal M., et al. Prognostic significance of histopathological parameters in sentinel nodes of melanoma patients. Histopathology 2007, 50:764-772.
19. Balch C.M., Soong S.J., Murad T.M., et al. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 1983, 1:126-134.
20. Buzzell R.A., Zitelli J.A. Favorable prognostic factors in recurrent and metastatic melanoma. J Am Acad Dermatol 1996, 34:798-803.
21. Balch C.M., Soong S.J., Gershenwald J.E. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001, 19:3622-3634.
22. Neuman H.B., Patel A., Ishill M. A single-institution validation of the AJCC staging system for stage IV melanoma. Ann Surg Oncol 2008, 15:2034-2041.
23. Rutkowski P., Nowecki Z.I., Dziewirski W., et al. Melanoma without a detectable primary site with metastases to lymph nodes. Dermatol Surg 2010, 36:828-876.
24. Katz K.A., Jonash E., Hodi F.S., et al. Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. Melanoma Res 2005, 14:77-82.
25. Lee C.C., Fairies M.B., Wanek L.A., et al. Improved survival for stage IV melanoma from an unknown primary site. J Clin Oncol 2009, 27:3489-3495.
26. Soong S.J., Ding S., Coit D., et al. Predicting survival outcome of localized melanoma: an electronic prediction tool based on the AJCC melanoma database. Ann Surg Oncol 2010, 17:2006-2014.
27. Soong S.J., Ding S., Coit D., et al. Models of predicting melanoma outcome. Cutaneous melanoma 2009, 87-104. Quality Medical Publishing, St Louis (MO). 5th edition. C.M. Balch, A.N. Houghton, A.J. Sober (Eds.).
28. Lasithiotakis K., Leiter U., Meier f, et al. Age and gender are significant independent predictors of survival in primary cutaneous melanoma. Cancer 2008, 112:1795-1804.
29. Pollack L.A., Li J., Berkowitz Z., et al. Melanoma survival in the United States, 1992 to 2005. J Am Acad Dermatol 2011, 65:S78-S86.
30. Ferrari A., Bono A., Baldi M., et al. Does melanoma behave differently in younger children than in adults? A retrospective study of 33 cases of childhood melanoma from a single institution. Pediatrics 2005, 115:640-654.
31. Livestro D.P., Kaine E.M., Michaelson J.S., et al. Melanoma in the young: differences and similarities with adult melanoma: a case-matched controlled analysis. Cancer 2007, 110:614-624.
32. Moore-Olufemi S., Herzog C., Warneke C., et al. Outcomes in pediatric melanoma: comparing prepubertal to adolescent pediatric patients. Ann Surg 2011, 253:1211-1215.
33. Joosse A., de Vries E., Eckel R., et al. Gender differences in melanoma survival: female patients have a decreased risk of metastasis. J Invest Dermatol 2011, 131:719-726.
34. Lachiewicz A.M., Berwick M., Wiggins C.L., et al. Survival differences between patients with scalp or neck melanoma and those with melanoma of other sites in the surveillance, epidemiology, and end results (SEER) program. Arch Dermatol 2008, 144:515-521.
35. Bichakjian C.K., Halpern A.C., Johnson T.M., et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol 2011, 65:1032-1047.
36. Colegio O.R., Proby C.M., Bordeaux, et al. Prognosis of pretransplant melanoma, letter to the editor. Am J Transplant 2009, 9:862.
37. Dapprich D.C., Weenig R.H., Rohlinger A.L., et al. Outcomes of melanoma in recipients of solid organ transplant. J Am Acad Dermatol 2008, 59:405-417.
38. Zwald F.O., Christenson L.J., Billingsley E.M., et al. Melanoma in solid organ transplant recipients. Am J Transplant 2010, 10:1297-1304.
39. Brewer J.D., Christenson L.J., Weaver A.L., et al. Malignant melanoma in solid transplant recipients: collection of database cases and comparison with surveillance, epidemiology, and end results data for outcome analysis. Arch Dermatol 2011, 147:790-796.
40. Burke M.M., Kluger H.M., Golden M., et al. Case report: response to ipilimumab in a patient with HIV with metastatic melanoma. J Clin Oncol 2011, 29:e792-e794.
41. Rodrigues L.K., Klencke B.J., Vin-Christian K., et al. Altered clinical course of malignant melanoma in HIV-positive patients. Arch Dermatol 2002, 138:765-770.
42. Shiu M.H., Schottenfeld D., Maclean B., et al. Adverse effect of pregnancy on melanoma: a reappraisal. Cancer 1976, 37:181-187.
43. Reintgen D.S., McCarty K.S., Vollmer R., et al. Malignant melanoma and pregnancy. Cancer 1985, 55:1340-1344.
44. Houghton A.N., Flannery J., Viola M.V. Malignant melanoma of the skin occurring during pregnancy. Cancer 1981, 48:407-410.
45. O'Meara A.T., Cress R., Xing G., et al. Malignant melanoma in pregnancy: a population-based evaluation. Cancer 2005, 103:1217-1226.
46. Pages C., Robert C., Thomas L. Management and outcome of metastatic melanoma during pregnancy. Br J Dermatol 2010, 162:274-281.
47. Jhaveri M.B., Driscoll M.S., Grant-Kels J.M. Melanoma in pregnancy. Clin Obstet Gynecol 2011, 54:537-545.
48. Driscoll M.S., Grant-Kels J.M. Hormones, nevi, and melanoma: an approach to the patient. J Am Acad Dermatol 2007, 57:919-931.
49. Wu X.C., Eide M.J., King J., et al. Racial and ethnic variations in incidence and survival of cutaneous melanoma in the United States, 1999-2006. J Am Acad Dermatol 2011, 65:S26-S37.
50. Eide M.J., Weinstock M.A., Clark M.A. Demographic and socioeconomic predictors of melanoma prognosis in the United States. J Health Care Poor Underserved 2009, 20:227-245.
51. Grimm E.A., Hoon D.S., Duncan L.M. Biomarkers for melanoma. Cutaneous melanoma 2009, 883-897. Quality Medical Publishing, St Louis (MO). 5th edition. C.M. Balch, A.N. Houghton, A.J. Sober (Eds.).
52. Utikal J., Schadendorf D., Ugurel S. Serologic and immunohistochemical prognostic biomarkers. Arch Dermatol Res 2007, 298:469-477.
53. Haass N.K., Smalley K.S. Melanoma biomarkers: current status and utility in diagnosis, prognosis, and response to therapy. Mol Diagn Ther 2009, 13:283-296.
54. Gould-Rothberg B.E., Bracken M.B., Rimm D.L. Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2009, 101:452-474.
55. Gould-Rothberg B.E., Rimm D.L. Biomarkers: the useful and the not so useful - an assessment of molecular prognostic markers for cutaneous melanoma. J Invest Dermatol 2010, 130:1971-1987.
56. Schramm S.J., Mann G.J. Melanoma prognosis: a REMARK-based systematic review and bioinformatic analysis of immunohistochemical and gene microarray studies. Mol Cancer Ther 2011, 10:1520-1528.
57. Schramm S.J., Campain A.E., Scolyer R.A., et al. Review and cross-validation of gene expression signatures and melanoma prognosis. J Invest Dermatol 2012, 132:274-283.
58. Elder D.E. Prognostic models for melanoma: invited review. J Cutan Pathol 2010, 37(Suppl 1):68-75.
59. Gershenwald J.E., Soong S.J., Balch C.M., et al. 2010 TNM staging system for cutaneous melanoma...and beyond. Ann Surg Oncol 2010, 17:1475-1477. [editorial].
60. Hocker T.L., Singh M.K., Tsao H. Melanoma genetics and therapeutic approaches in the 21st century: moving from the bench side to the bedside. J Invest Dermatol 2008, 128:2575-2595.
61. Smalley K.S. Understanding melanoma signaling networks as the basis for molecular targeted therapy. J Invest Dermatol 2010, 130:28-37.
62. Flaherty K.T. Is it good or bad to find a BRAF mutation?. J Clin Oncol 2011, 29:1229-1230.
63. Long G.V., Menzies A.M., Nagrial A.M., et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011, 29:1239-1246.
64. Flaherty K.T., Puzanov I., Kim K.B., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363:809-819.
65. Amaya V., Fridlyand J., Bauer J., et al. Improving melanoma classification by integrating genetic and morphologic features. PLoS Med 2008, 5:941-951.